Background. There is currently an experts' agreement discouraging interruption of antiretroviral treatment (ART) during the first trimester of pregnancy in women infected with human immunodeficiency virus type 1 (HIV-1). However, this recommendation is poorly supported by data. We evaluated the effects of discontinuing ART during pregnancy on the rate of mother-to-child transmission.
(MTCT) of HIV-1 [2] [3] [4] [5] . In developed countries, the synergic effect of ART in the mother and newborn, cesarean delivery, and avoidance of breast-feeding have resulted in a rate of MTCT of !2% [2] [3] [4] [5] . In the HAART era, the rate of MTCT is ∼1%, probably because of the strong effect of HAART on the maternal viral load [6] . Therefore, there is a consensus on the benefits of HAART for the mother's health and for prevention of MTCT, provided that drugs with a potential toxicity for the offspring are avoided [7] . Data from prospective registries [8] support lack of teratogenicity with exposure to antiretroviral drugs during pregnancy, but with the increasing use of new molecules, monitoring of birth defects is continually needed. An increasing number of treated women are now identified as pregnant, and presently there is an experts' opinion discouraging a temporary discontinuation of ART during the first trimester [7] . However, this opinion is only partially supported by evidence. To date, insufficient data support an increase in the rate of MTCT as a consequence of ART discontinuation during pregnancy. We performed an analysis involving a large cohort of children prospectively enrolled in the Italian Register for HIV Infection in Children, to evaluate the effect of discontinuation of ART during pregnancy on the rate of MTCT.
METHODS

Data collection. The Italian Register for HIV Infection in
Children is a nationwide multicenter study of children perinatally exposed to HIV-1 that was instituted in 1985. Data come from a network of 106 participating pediatric centers located throughout Italy, representing the overall population of exposed infants in Italy [3] . Informed consent at the local pediatric center and National Privacy Agency permission are obtained. Both at-risk children identified at birth and infected children identified after birth are enrolled. In this study, only exposed children identified at birth who were born to treated mothers and who had known infectious status were considered [3] . Data with regard to mother-infant pairs were collected as described elsewhere [3, 9] . Detailed data on the type of regimen(s), gestational age at beginning and end of ART (for each single regimen if switches occurred during pregnancy), and ART administered intrapartum and/or to the newborn were included. Maternal data were obtained at each pediatric center from an infectious diseases report and/or a gynecologist's report, and they were recorded at the infant's first examination, at birth. From 2001, information on the maternal plasma viral RNA load and CD4 + cell counts at the time of delivery and information on the last antiretroviral regimen (the type and the date of initiation) prior to pregnancy were collected. Because this information was uniformly available only since 2002, only children born in 2002 or later were evaluated in the present study. Viral loads and CD4 + cell counts were evaluated as described elsewhere [3, 9] . Both baseline and follow-up information on the infant's infection status, HIV-1 antibodies, and viral markers (HIV-1 DNA or RNA detection) were collected [3] .
Case definition. Infection in children [3, 9, 10] , elective cesarean delivery [2] , and duration of ART during pregnancy [9] were defined as reported. To evaluate the effect of type of ART on the rate of MTCT, we defined monotherapy as zidovudine (according to the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group protocol), double therapy as any regimen including 2 nucleoside reverse-transcriptase inhibitors (NRTI), and HAART as any combination regimen with у3 antiretroviral drugs (no mother received a triple NRTI regimen). Among HAART regimens, a nevirapine-based regimen was defined as any triple regimen including 2 NRTIs plus nevirapine, and a protease inhibitor (PI)-based regimen was defined as any triple (or more) regimen including NRTIs plus a PI. When 11 regimen was received during pregnancy, the more complex (i.e., HAART vs. double) was considered. Maternal interruption of ART was defined as the discontinuation of any ART for 115 days. Shorter periods of interruption, in fact, could not be reported by the mothers. Moreover, it is usually believed that plasma viral RNA load significantly decreases after 2 weeks of treatment, and perinatal guidelines recommend monitoring maternal viral load 2-6 weeks after initiating or changing ART [7] . The gestational age at ART initiation was defined as the week at the beginning of the first ART regimen for women who did not receive therapy during the periconceptional period. Data were expressed as median and interquartile range (IQR) or as mean and 95% CI. Differences in proportions were evaluated by the x 2 test. A nonparametric 3-sample test was performed to test the hypothesis of median equality. The analysis of variance was used to test for differences in maternal viral load at delivery. To evaluate the association of ART interruption with the rate of MTCT, logistic regression models were performed to estimate adjusted ORs for factors potentially influencing the rate of MTCT: infant's sex, gestational age (!37 weeks, у37 weeks, or unknown), plasma viral RNA load at delivery (!2.6, 2.6-4.00, 4.01-5.78, 15 .78 log 10 copies/mL, or unknown), CD4
+ cell count at delivery (!200, 200-499, у500 cells/mL, or unknown), mode of delivery (vaginal delivery, elective cesarean delivery, cesarean delivery other than elective, or unknown), maternal ART in pregnancy (zidovudine monotherapy, double therapy, HAART, or unknown), maternal interruption of ART (yes or no), intrapartum ART (yes, no, or unknown), and neonatal ART (yes, no, or unknown). Because NOTE. HAART was defined as у3 antiretroviral drugs. ART, antiretroviral therapy.
no child was breast-fed, the mode of feeding was not included in the regression analyses. To better evaluate interaction between quantitative variables potentially associated with the rate of MTCT, an additional logistic regression model with log 10 plasma viral RNA load and log 10 CD4
+ cell count as continuous variables was performed for a subgroup of mother-child pairs with both variables known.
RESULTS
Mother-infant pairs. Overall, 937 of 1016 mother-child pairs receiving ART entered the study; 79 (7.8%) of the exposed infants were excluded because they were lost to follow-up before ascertainment of infectious status. The characteristics of the 937 mothers and children are shown in ). The maternal viral load P p .966 decreased as the complexity of the ART regimen increased. The mean plasma viral load was 2.6 log 10 copies/mL (95% CI, 2.2-2.9 log 10 copies/mL), 2.4 log 10 copies/mL (95% CI, 2.2-2.6 log 10 copies/mL), and 1.9 log 10 copies/mL (95% CI, 1.8-2.0 log 10 copies/mL) in women receiving monotherapy, double therapy, or HAART, respectively (analysis of variance, ; F p 17.2 P ! ). The median gestational age at the beginning of treatment .001 was 18 weeks (IQR, 13-35 weeks), 18 weeks (IQR, 13-25 weeks), and 13 weeks (IQR, 6-22 weeks) in women receiving monotherapy, double therapy, or HAART, respectively, thus decreasing with the increase in the ART complexity (x 2 p 36.8; ). The proportion of women with detectable viral load P ! .001 did not differ according to trimester at start of ART when monotherapy was given ( ; 78.6% during the first trin p 50 mester, 55.0% during the second trimester, and 56.3% during the third trimester; x 2 p 2.27; ) In addition, the pro-P p .321 ). P ! .001 Women treated with HAART who had a known plasma viral load had similar mean plasma viral loads when 281 women who were treated with a PI-based regimen (1.95 log 10 copies/ mL; 95% CI, 1.77-2.07 log 10 copies/mL) were compared with 328 women treated with a nevirapine-based regimen (1.85 log 10 copies/mL; 95% CI, 1.65-1.92 log 10 copies/mL; Student's t test, 1.29;
). P p . ). P ! .001 We checked whether women switched therapy after interruption to a less or more active regimen, but the proportions of women treated with a nevirapine-or PI-based HAART regimen before or after treatment interruption were similar (table  1) . Treatment was restarted with the same class of antiretroviral drugs in 47 (58.0%) of the 81 women, among whom 19 (23.5%) received the same nevirapine-based regimen that they received prior to the interruption.
Among women whose viral load at delivery was known, the mean plasma viral load was similar in those who had treatment interrupted in the first trimester (2.04 log 10 copies/mL; 95% CI, 1.81-2.26 log 10 copies/mL) and in those who did not have treatment interrupted (2.04 log 10 copies/mL; 95% CI, 1.95-2.14 log 10 copies/mL; Student's t test, Ϫ0.04;
). Similarly, P p .967 the mean CD4 + cell count at delivery was similar in women who had treatment interrupted (2.63 log 10 cells/mL; 95% CI, 2.57-2.69 log 10 cells/mL) and in those who did not have treatment interrupted (2.65 log 10 cells/mL; 95% CI, 2.65-2.67 log 10 cells/mL; Student's t test, Ϫ0.40;
). Among HAART-P p .689 treated women who had therapy interrupted and who had known plasma viral load, we found no difference in mean plasma viral load between 29 women treated with a PI-based regimen (2.06 log 10 copies/mL; 95% CI, 1.70-2.42 log 10 copies/ mL) and 28 women treated with a nevirapine-based regimen (1.85 log 10 copies/mL; 95% CI, 1.69-2.01 log 10 copies/mL; Student's t test, 1.12;
). P p .268 MTCT rate and confounding factors. Overall, the rate of MTCT in the whole cohort was 1.3% (95% CI, 0.7%-2.3%). The rate of MTCT among children born to mothers who had ART interrupted in the first trimester was 4.9% (95% CI, 1.9%-13.2%), and the rate of MTCT among children born to mothers who had ART interrupted in the third trimester was 18.2% (95% CI, 4.5%-72.7%). Characteristics of the 12 mother-child pairs in which the children were infected are shown in table 2. To evaluate the role of different risk factors for MTCT, univariate and multiple logistic regression models were performed. Maternal monotherapy or double therapy, interruption of ART during either the first or the third trimester, delivery by a mode other than elective cesarean delivery, and a viral load at delivery 14.78 log 10 copies/mL were associated with an increased rate of MTCT (table 3) . Plasma viral load 14.78 log 10 copies/mL was associated with a 30-fold increased risk of transmission.
Other factors (maternal CD4 + cell count at delivery, trimester at the start of ART, child's sex, and intrapartum and neonatal ART) were not significantly associated with the rate of MTCT.
When we included in an additional model the 79 exposed infants lost to follow-up, with the assumption that all these children were uninfected, results were unchanged (adjusted OR for treatment interruption in the first trimester, 11.4; in the third trimester, 34.1). The probability of infection in children in this group was very low, because missing infected children are regained by periodical cross-matches with the Italian National AIDS Registry, to which all AIDS cases must be reported [11] .
To check the interference of missing values for maternal plasma viral load, 3 logistic regression models were performed. Interruption of ART in the first trimester was associated with an adjusted OR of 10.33 (95% CI, 2.02-52.91; ), and P p .005 interruption of ART in the third trimester was associated with an adjusted OR of 46.86 (95% CI, 4.28-512.64; ) in P p .002 the whole cohort, with the inclusion of maternal viral load as a category with missing values. When only cases with known maternal viral load were included, the adjusted OR for interruption of ART in the first trimester was 11.45 (95% CI, 1.58-83.08;
) and in the third trimester was 24.33 (95% CI, P p .016 0.77-765.92;
). When maternal viral load was ex-P p .070 cluded, the adjusted OR for interruption of ART in the first trimester was 8.32 (95% CI, 1.88-36.90;
) and in the P p .005 third trimester was 40.52 (95% CI, 4.24-387.64; ) in P p .001 the whole cohort.
Finally, a logistic regression model on a subgroup (n p ) of mother-child pairs with both known plasma viral load 538 and known CD4 + cell count was performed, including these factors as continuous variables. Treatment interruption in the first trimester was associated with an adjusted OR of 10.70 (95% CI, 1.48-77.18), and treatment interruption in the third trimester was associated with an adjusted OR of 30.38 (95% CI, 0.98-941.66). Plasma viral load was associated with an adjusted OR of 2.50 (95% CI, 1.27-4.91), and CD4 + cell count was associated with an adjusted OR of 1.87 (95% CI, 0.07-53.26). Thus, treatment interruption in the first trimester was associated with a 10-fold increased risk of MTCT, whereas a plasma viral load increase of 1 log 10 copies/mL doubled the risk of MTCT.
DISCUSSION
To our knowledge, this is the first study to reveal that discontinuing ART during pregnancy increases the rate of MTCT of HIV-1, either when ART is stopped in the first trimester and subsequently restarted, or when it is interrupted in the third trimester. The last finding was partly expected, because discontinuation of treatment could lead to a viremic rebound [12, 13] and because a higher viral load near the time of delivery increases the risk of MTCT, as we and others have clearly shown [14, 15] . The incremental risk of MTCT associated with treatment interruption is high among all treated women, even among HAART-treated women, maybe because the viremic rebound is stronger if the virological potency of therapy is higher. Therefore, our findings confirm the recommendation that pregnant women infected with HIV-1 who receive ART should continue treatment after the first trimester, particularly at the end of pregnancy [7] . More interestingly, we found that interruption of ART early in pregnancy increased the rate of MTCT both in the whole cohort and among children born to HAARTtreated women. To our knowledge, no other large study has investigated this issue. Of note, in our cohort, temporary ART discontinuation early in pregnancy is more frequent in women receiving HAART, probably because of the fear of drug toxicity in the embryo. However, temporary discontinuation led to a 10-fold increase in the rate of MTCT, overcoming all other risk factors, except for the independent factor of high plasma viral RNA load at delivery. When viral load increased by 1 log 10 copies/mL, the risk of MTCT was, indeed, more than doubled. A small proportion of HAART-treated women may have high plasma viral loads because of poor compliance or mutations associated with viral resistance [16] . Nevertheless, we found no difference in predelivery plasma viral load between mothers who temporarily discontinued therapy and mothers who did not. It might be speculated that a transient viral load increase, occurring close to the time of ART interruption, favors HIV-1 transmission.
We also investigated whether a lower antiretroviral potency of the regimen administered after suspension could lead to higher risk of MTCT, but the proportions of nevirapine-based or PI-based regimens were similar before and after interruption. However, it is possible that virological failure occurred more frequently because of nevirapine-resistance mutations [17] in those women who discontinued and restarted the same nevirapine-based regimen. Viral load at delivery was similar in the women treated with a PI-based regimen and in those treated with a nonnucleoside reverse-transcriptase inhibitor-based regimen in both the whole cohort and in those who had therapy interrupted. In addition, we found a trend toward higher viral loads in women treated with a PI-based regimen than in those treated with an nonnucleoside reverse-transcriptase inhibitorbased regimen, as recently was reported by the European Collaborative Study [18] . It is possible that women with lower baseline viral loads (before or at the beginning of pregnancy) are more often treated with nonnucleoside reverse-transcriptase inhibitor-based regimens, or the pharmacokinetic peculiarities of ART in pregnancy may be involved [18] .
Because our data are from a large pediatric cohort, a limitation in our analyses is that some detailed information on the mothers was lacking. First of all, maternal viral load at delivery was unknown for ∼30% of mother-child pairs. However, when mother-child pairs were compared according to whether maternal viral load was known or unknown, exactly the same MTCT rate was found. As an additional check, 3 different logistic regression models were performed, but the main role of ART interruption in pregnancy was constantly confirmed. Another critical point is the unavailability in our database of information on the reasons for ART discontinuation during pregnancy. Therapy could be discontinued for several reasons: the development of virological failure or resistance mutations, the occurrence of adverse effects, or the desire to avoid fetal exposure during the first trimester. On the other hand, ART interruption was not homogeneously distributed during the whole pregnancy, peaking at 6 and 32 weeks. We think that avoidance of fetal exposure during the first trimester and intolerance of treatment are the most probable reasons for ART discontinuation, and if so, it would be unlikely that women who had ART suspended were a priori at higher risk of MTCT because of virological failure or resistance mutations. Unfortunately, we had no data on maternal viral load during gestation. Moreover, we could not assess whether infected children born to mothers who had ART interrupted acquired the infection in utero or perinatally [19] , because we do not systematically measure HIV-1 RNA or DNA load during the first 24-48 h of life.
We investigated all interactions between variables that we thought were biologically convincing. Other important factors might be compliance to ART and genotype resistance in the mothers, but these data were lacking in our database. Finally, the very low number of infected children in the whole cohort and, consequently, the wide 95% CIs found, are additional caveats. Additional studies, prospectively performed using large cohorts of mother-child pairs starting from the beginning of gestation, may confirm our findings. It may be surprising that we found no relationship between intrapartum and neonatal therapy and the rate of MTCT, but the numbers of motherchild pairs who were not receiving intrapartum and neonatal prophylaxis were too small to draw any conclusion. Moreover, we found no differences according to trimester at start of ART, even if a higher proportion of HAART-treated women had a detectable viral load at delivery when treatment was used during the third trimester, compared with the first or second trimester. This finding supports recently revised guidelines [7] that recommend that, in women who do not require ART for their own health, ART for MTCT prophylaxis may be started during the second trimester, preferably with a 3-drug regimen.
The main finding of our study is that no other factors but the discontinuation of ART and high maternal viral load at delivery are associated with an increased risk of MTCT. Thus, although concerns about potential toxicity in the fetus need to be completely clarified, counseling on the temporary discontinuation of ART in the first trimester should consider both the need for maternal health [7] and the increased risk of HIV-1 transmission to the offspring. We believe that our findings may be useful for physicians who care for women infected with HIV-1 and for specialists who determine guidelines.
